Respiratory sEMG in dyspneic children before and after treatment with Salbutamol.

Recruiting

• Conditions: Asthma Dyspnea; 10024967

• Registration Number: NL-OMON52077
• Lead Sponsor: Asthmaware

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

a)
• Diagnosed or suspected with Asthma
• Having a reversibility test scheduled
• Age 5-10 yrs

b)
• Acute Dyspnea
• Treated with Salbutamol at the ER Unit
• Age 3-10 yrs

Exclusion Criteria

• Congenital diseases that can cause dyspnea, i.e. severe congenital heart
defects or Cystic Fybrosis
• History of Herniated Diaphragm
• Allergy of EMG-electrodes
• Ex-prematures with a gestational age at birth <37 wks
• Pneumonia without signs of asthma or bronchial hyperresponsiveness
• Laryngitis subglottica

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary endpoint is the difference between EMG-measured muscle activity of the<br /><br>diaphragm before and after Salbutamol administration. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints are:<br /><br>• Correlation between the change in EMG-measured diaphragmatic muscle activity<br /><br>and the change in CAS values in acute dyspnoeic children.<br /><br>• Correlation between the change in EMG-measured diaphragmatic muscle activity<br /><br>and the change in Borg values in acute dyspnoeic children.<br /><br>• Correlation between the change in EMG-measured diaphragmatic muscle activity<br /><br>and the change in FEV1 values in non-acute dyspnoeic children. </p><br>